Latest & greatest articles for chlorthalidone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chlorthalidone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chlorthalidone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chlorthalidone

1. Chlorthalidone

Chlorthalidone Top results for chlorthalidone - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for chlorthalidone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. How do hydrochlorothiazide and chlorthalidone compare for treating hypertension?

How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? View/ Open Date 2014-04 (...) Format Metadata Abstract Q. How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? A. Both medications reduce theincidence of cardiovascular events in patients with hypertension, but chlorthalidone may confer additional cardiovascular risk reduction (strength of recommendation [SOR]: B, conflicting network meta-analysis and cohort studies). (No head-to-head studies of hydrochlorothiazide [HCTZ] and chlorthalidone have been done.) Serious hypokalemia and hyponatremia can

2014 Clinical Inquiries

3. Azilsartan medoxomil + chlorthalidone - Hypertension, essential

Azilsartan medoxomil + chlorthalidone - Hypertension, essential Common Drug Review CDEC Meeting — September 18, 2013 Notice of CDEC Final Recommendation – October 17, 2013 Page 1 of 4 © 2013 CADTH CDEC FINAL RECOMMENDATION AZILSARTAN MEDOXOMIL / CHLORTHALIDONE (Edarbyclor — Takeda Canada Inc.) Indication: Severe Hypertension Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that azilsartan medoxomil/chlorthalidone (AZL-M/CLD) not be listed. Reason for the Recommendation: CDEC (...) hypertension in Canada. Background: Edarbyclor is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a diuretic. Edarbyclor has a Health Canada indication for initial therapy for patients with severe essential hypertension in whom the benefits of prompt blood pressure reduction exceed the risks of combination therapy. The typical starting combined dose is 40 mg/12.5 mg (AZL-M/CLD) taken orally once daily. The dose can be increased to 80 mg/12.5

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

4. Chlorthalidone for hypertensive patients

Chlorthalidone for hypertensive patients Chlorthalidone for hypertensive patients Chlorthalidone for hypertensive patients Malaysian Health Technology Assessment (MaHTAS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Malaysian Health Technology Assessment (MaHTAS). Chlorthalidone for hypertensive patients . Putrajaya: Malaysian Health (...) Technology Assessment (MaHTAS). 2013 Authors' objectives To review evidence on the safety, efficacy/effectiveness and cost-effectiveness of Chlorthalidone to reduce cardiovascular events compared with current practice with hydrochlorothiazide. Authors' conclusions The studies available were of good level but limited evidence to show Chlorthalidone could reduce cardiovascular events in hypertensive patients. Final publication URL INAHTA brief and checklist INAHTA brief and checklist Indexing Status

2013 Health Technology Assessment (HTA) Database.

5. Azilsartan Medoxomil + Chlorthalidone (Edarbyclor- Takeda Canada Inc.) indication: severe hypertension

Azilsartan Medoxomil + Chlorthalidone (Edarbyclor- Takeda Canada Inc.) indication: severe hypertension Azilsartan Medoxomil + Chlorthalidone (Edarbyclor- Takeda Canada Inc.) indication: severe hypertension Azilsartan Medoxomil + Chlorthalidone (Edarbyclor- Takeda Canada Inc.) indication: severe hypertension CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation CADTH. Azilsartan Medoxomil + Chlorthalidone (Edarbyclor- Takeda Canada Inc.) indication: severe hypertension. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2013 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that azilsartan medoxomil/chlorthalidone (AZL-M/CLD) not be listed. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Benzimidazoles; Chlorthalidone; Drug Therapy

2013 Health Technology Assessment (HTA) Database.

6. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses

Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses Roush GC, Holford TR, Guddati AK CRD summary This review and network meta-analysis concluded that chlortalidone (...) for practice. Research : The authors stated that more research was needed into evening dosing and the duration of the effects of hydrochlorothiazide, compared with chlortalidone. Funding Not stated. Bibliographic details Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012; 59(6): 1110-1117 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Adult

Full Text available with Trip Pro

2012 DARE.

7. The legacy effect: 4.5 years of a chlorthalidone-based antihypertensive regimen reduces cardiovascular mortality and prolongs cardiovascular disease-free survival at 22 years for older patients with isolated systolic hypertension

The legacy effect: 4.5 years of a chlorthalidone-based antihypertensive regimen reduces cardiovascular mortality and prolongs cardiovascular disease-free survival at 22 years for older patients with isolated systolic hypertension The legacy effect: 4.5 years of a chlorthalidone-based antihypertensive regimen reduces cardiovascular mortality and prolongs cardiovascular disease-free survival at 22 years for older patients with isolated systolic hypertension | BMJ Evidence-Based Medicine We use (...) accounts Username * Password * your user name or password? You are here The legacy effect: 4.5 years of a chlorthalidone-based antihypertensive regimen reduces cardiovascular mortality and prolongs cardiovascular disease-free survival at 22 years for older patients with isolated systolic hypertension Article Text Therapeutics The legacy effect: 4.5 years of a chlorthalidone-based antihypertensive regimen reduces cardiovascular mortality and prolongs cardiovascular disease-free survival at 22 years

2012 Evidence-Based Medicine (Requires free registration)

8. Edarbyclor (azilsartan medoxomil and chlorthalidone)

Edarbyclor (azilsartan medoxomil and chlorthalidone) Drug Approval Package:Edarbyclor (azilsartan medoxomil and chlorthalidone) NDA #202331 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Edarbyclor (azilsartan medoxomil and chlorthalidone) Tablets, 40/12.5 and 40/25 mg Company: Takeda Pharmaceuticals North America Application No.: 202331 Approval Date: 12/20/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796

2011 FDA - Drug Approval Package

9. Association between chlorthalidone treatment of systolic hypertension and long-term survival. (PubMed)

Association between chlorthalidone treatment of systolic hypertension and long-term survival. In the Systolic Hypertension in the Elderly Program (SHEP) trial, conducted between 1985 and 1990, antihypertensive therapy with chlorthalidone-based stepped-care therapy resulted in a lower rate of cardiovascular events than placebo but effects on mortality were not significant.To study the gain in life expectancy of participants randomized to active therapy at the 22-year follow-up.A National Death (...) ). Time to 70th percentile survival was 0.56 years (95% CI, -0.14 to 1.23) longer in the active treatment group vs the placebo group (11.53 vs 10.98 years; P = .03) for all-cause mortality and 1.41 years (95% CI, 0.34-2.61; 17.81 vs 16.39 years; P = .01) for survival free from cardiovascular death.In the SHEP trial, treatment of isolated systolic hypertension with chlorthalidone stepped-care therapy for 4.5 years was associated with longer life expectancy at 22 years of follow-up.

Full Text available with Trip Pro

2011 JAMA Controlled trial quality: predicted high

10. Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients

Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients Article Text

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

11. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. (PubMed)

Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. Few cardiovascular outcome data are available for blacks with hypertension treated with angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs).To determine whether an ACE inhibitor or CCB is superior to a thiazide-type diuretic in reducing cardiovascular disease (CVD) incidence in racial subgroups.Prespecified subgroup analysis of ALLHAT, a randomized, double (...) -blind, active-controlled, clinical outcome trial conducted between February 1994 and March 2002 in 33,357 hypertensive US and Canadian patients aged 55 years or older (35% black) with at least 1 other cardiovascular risk factor.Antihypertensive regimens initiated with a CCB (amlodipine) or an ACE inhibitor (lisinopril) vs a thiazide-type diuretic (chlorthalidone). Other medications were added to achieve goal blood pressures (BPs) less than 140/90 mm Hg.The primary outcome was combined fatal coronary

Full Text available with Trip Pro

2005 JAMA

12. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. (PubMed)

Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. 15238589 2004 07 13 2016 10 17 1538-3598 292 1 2004 Jul 07 JAMA JAMA Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. 43-4 Psaty Bruce M BM Lumley Thomas T Furberg Curt D CD eng Letter Meta-Analysis United States JAMA 7501160 0098-7484 0 Antihypertensive Agents 0 Diuretics Q0MQD1073Q Chlorthalidone AIM IM JAMA. 2004 Oct (...) 20;292(15):1816-7; author reply 1817 15494575 Antihypertensive Agents therapeutic use Chlorthalidone therapeutic use Coronary Disease prevention & control Diuretics therapeutic use Humans Hypertension drug therapy Treatment Outcome 2004 7 9 5 0 2004 7 14 5 0 2004 7 9 5 0 ppublish 15238589 10.1001/jama.292.1.43-c 292/1/43-b

2004 JAMA

13. Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension

Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension Article Text Therapeutics Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD

Full Text available with Trip Pro

2004 Evidence-Based Medicine (Requires free registration)

14. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. (PubMed)

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. Hypertension is associated with a significantly increased risk of morbidity and mortality. Only diuretics and beta-blockers have been shown to reduce this risk in long-term clinical trials. Whether newer antihypertensive agents reduce the incidence of cardiovascular disease (...) (CVD) is unknown.To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril.Randomized, double-blind, active-controlled clinical trial, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, initiated in February 1994. In January 2000, after an interim analysis, an independent data

2000 JAMA Controlled trial quality: predicted high

15. Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension. A multicenter study. (PubMed)

Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension. A multicenter study. We compared a new low-dose chlorthalidone formulation consisting of 15 mg of this compound and a biocompatible polymer in a double-blind placebo-controlled trial with the standard 25-mg dose of chlorthalidone in the management of mild essential hypertension. Two hundred twenty-two patients, ranging in age from 21 to 69 years, with an average standing (...) of chlorthalidone appears to be an effective antihypertensive agent with fewer metabolic side effects compared with the standard 25-mg dose in the management of mild essential hypertension.

1987 JAMA Controlled trial quality: uncertain

16. Low doses v standard dose of reserpine. A randomized, double-blind, multiclinic trial in patients taking chlorthalidone. (PubMed)

Low doses v standard dose of reserpine. A randomized, double-blind, multiclinic trial in patients taking chlorthalidone. Reserpine in different doses was assigned in random, double-blind fashion to 329 patients with mild to moderate hypertension who had not achieved normotension with chlorthalidone therapy alone. The additional reduction of BP averaged 11.0/10.4 mm Hg with chlorthalidone, 50 mg, plus reserpine, 0.25 mg (C 50+R 0.25); 9.5/9.4 mm Hg with C 50+R 0.125; 6.4/8.5 mm Hg with C 50+R

1982 JAMA Controlled trial quality: uncertain

17. Serum lipoprotein levels during chlorthalidone therapy. A Veterans Administration-National Heart, Lung, and Blood Institute cooperative study on antihypertensive therapy: mild hypertension. (PubMed)

Serum lipoprotein levels during chlorthalidone therapy. A Veterans Administration-National Heart, Lung, and Blood Institute cooperative study on antihypertensive therapy: mild hypertension. In a joint Veterans Administration-National Heart, Lung, and Blood Institute study of mild hypertension, 1,012 men and women, 21 to 50 years of age and with diastolic pressure from 85 to 105 mm Hg, were randomized into two double-blind treatment groups. Subjects in the active group received chlorthalidone (...) or chlorthalidone plus reserpine, while the other subjects received matching placebo tablets. After one year of treatment, the chlorthalidone group had increases of 10.0 +/- 1.8 (SE) mg/dL in total cholesterol level, 9.8 +/- 5.2 mg/dL in triglyceride level, and 12.6 +/- 3.4 mg/dL in low-density lipoprotein-cholesterol level above the changes in the placebo group. There was no difference in high-density lipoprotein changes between the two groups (0.1 +/- 0.8 mg/dL). The possible net effect on risk of increasing

1980 JAMA Controlled trial quality: uncertain

18. [The antihypertensive effect of a new beta-adrenergic blocking drug metroprolol in combination with chlorthalidone]. (PubMed)

[The antihypertensive effect of a new beta-adrenergic blocking drug metroprolol in combination with chlorthalidone]. 7445 1976 10 01 2013 11 21 0012-7183 92 11 1976 Duodecim; laaketieteellinen aikakauskirja Duodecim [The antihypertensive effect of a new beta-adrenergic blocking drug metroprolol in combination with chlorthalidone]. 597-603 Jäättelä A A Pyöräiä K K fre Clinical Trial Controlled Clinical Trial English Abstract Journal Article Randomized Controlled Trial Uuden beetasalpaajan (...) metoprololin ja klortalidonin yhdistelmä hypertonian hoidossa Finland Duodecim 0373207 0012-7183 0 Adrenergic beta-Antagonists 0 Propanolamines Q0MQD1073Q Chlorthalidone IM Adrenergic beta-Antagonists therapeutic use Adult Aged Chlorthalidone therapeutic use Clinical Trials as Topic Drug Evaluation Drug Therapy, Combination Female Humans Hypertension drug therapy Male Middle Aged Propanolamines therapeutic use 1976 1 1 1976 1 1 0 1 1976 1 1 0 0 ppublish 7445

1976 Duodecim; laaketieteellinen aikakauskirja